Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McKenna, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by McKenna, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 British Society for Rheumatology

Efficacy and gastroduodenal safety of a fixed combination of diclofenac and misoprostol in the treatment of arthritis

F. McKenna

Rheumatic Diseases Unit, Trafford General Hospital Moorside Road, Davyhulme, Manchester M41 5SL


  Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are an effective therapy for the management of arthritis, but their use is restricted by the risk of gastrointestinal complications from NSAID-induced ulceration. The elderly, in particular, are vulnerable to such damage and complications. Misoprostol is the only cytoprotective drug found to be effective in the prevention of both gastric and duodenal ulcers associated with NSAIDs. A fixed-combination of diclofenac 50 mg/misoprostol 200 µg has been evaluated for efficacy and safety in the treatment of arthritis. Pharmacokinetic studies of the fixed combination have found that no drug-drug interaction occurs between misoprostol and diclofenac after either single or multiple doses, and the bioavailability of misoprostol and diclofenac are comparable with that of misoprostol and diclofenac given alone. This fixed combination was found to be equivalent to other NSAIDs in the control of symptoms and other parameters of arthritis. The fixed combination was generally well tolerated, although the occurrence of abdominal pain and diarrhoea was slightly more frequent than with other NSAIDs. This contrasts with a 2- to 3-fold reduction in the rate of gastroduodenal damage with the fixed combination compared with the rate associated with other NSAIDs. These results indicate that the diclofenac 50 mg/misoprostol 200 µg combination should be considered in preference to other NSAIDs when treating patients at risk of ulcer complications.

KEY WORDS: Non-steroidal anti-inflammatory drugs, Rheumatoid arthritis, Osteoarthritis, Gastric ulcer, Duodenal ulcer, Misoprostol, Diclofenac


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.